Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07406360 · ClinicalTrials.gov registry record · Phase 3
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
A Phase 3 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,209
- Enrollment target
NCT07406360: Recruiting Phase 3 study, sponsored by GlaxoSmithKline.
NCT07406360 is a Phase 3 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,209 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07406360, a Phase 3 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,209 participants
- Enrollment target
Study Summary
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).
Interventions
- BIOLOGICAL MMRVNS
- BIOLOGICAL MMRV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,209 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2028-07-20 |
| Phase | Phase 3 |
What NCT07406360 shows while recruiting
NCT07406360 is an interventional study that assigns participants to a tested intervention. Its 1,209 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 2 interventions - of which MMRVNS is the first listed.
NCT07406360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07406360 about?
NCT07406360 is a clinical study titled "A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age". This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administer...
What is the current status of trial NCT07406360?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,209 participants. The study started on 2026-05-11. Estimated completion is 2028-07-20.
What interventions are being tested in trial NCT07406360?
The interventions under investigation include: MMRVNS (BIOLOGICAL), MMRV (BIOLOGICAL).
Who is sponsoring clinical trial NCT07406360?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07406360's enrollment target sits among peer trials
1,209 217th of 2000 higher than 1,783 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI